Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
暂无分享,去创建一个
John P Leonard | J. Leonard | A. Younes | N. Bartlett | A. Forero-Torres | Anas Younes | Nancy L Bartlett | Andres Forero-Torres | Dana A Kennedy | Eric L Sievers | E. Sievers | Carmel M Lynch | C. Lynch | D. Kennedy
[1] B. Labar,et al. Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin’s Disease , 2005, Oncology Research and Treatment.
[2] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Leone,et al. Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. , 2010 .
[4] A. van den Berg,et al. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. , 1999, The American journal of pathology.
[5] Jeffrey S. Miller,et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[7] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[8] J. Arezzo,et al. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. , 2008, Clinical advances in hematology & oncology : H&O.
[9] V. Diehl,et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. , 2005, Blood.
[10] W. Wilson,et al. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. T. te Meerman,et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22 , 2008, British journal of haematology.
[12] Kenji Matsumoto,et al. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. , 2004, Journal of immunology.
[13] H. Stein,et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.
[14] J. Garcia-conde,et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[16] Jennifer B. Webster,et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. , 2006, Protein engineering, design & selection : PEDS.
[17] F. Gherlinzoni,et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. , 2000, Haematologica.
[18] H. Gerber,et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma , 2008, British journal of haematology.
[19] Y. Oki,et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma , 2008, Cancer.
[20] S. Ansell,et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] V. Sondak,et al. Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Swain,et al. Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Diehl,et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. , 2005, Cancer research.
[24] F. Stirpe,et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. , 1995, Blood.
[25] V. Diehl,et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.
[26] A. Younes. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.
[27] L. Asmar,et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. , 2004, Clinical lymphoma.
[28] J. Leonard,et al. A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma , 2009, British journal of haematology.
[29] K. Aldape,et al. A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.
[30] A. Zelenetz,et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] S. Rule,et al. Vinorelbine in the treatment of lymphoma. , 1998, Hematological oncology.
[32] D. Longo,et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. , 1995, Cancer research.
[33] Michael M C Sun,et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.
[34] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .